Search Results
Your search for The ASCO Post Staff,The ASCO Post Staff matches 6163 pages
Showing 2451 - 2500Report Finds Uptake of Erdafitinib for Urothelial Cancer May Be Limited, Despite Positive Real-World Survival Data
The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a report published as a research letter by Nimgaonkar et al in JAMA Oncology. Researchers analyzed a large, nationwide database of cancer...
Pedro T. Ramirez, MD, on Hysterectomy for Early Cervical Cancer: New Findings on Open vs Minimally Invasive Surgery
Pedro T. Ramirez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final analysis of the LACC trial (Laparoscopic Approach to Cervical Cancer), which showed that women with early cervical cancer who need a radical hysterectomy may have worse outcomes with minimally invasive...
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses findings from the SORAYA study on the efficacy and safety of mirvetuximab soravtansine in patients who have platinum-resistant ovarian cancer with high folate receptor–alpha expression. Based on the results, Dr. Matulonis believes...
Delays in Surgery for Advanced Esophageal Cancer Result in Significantly Worse Survival
Delays in surgery for esophageal cancer did not appear to have much impact on patients’ relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an...
Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma
A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...
Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges
Nickolas Papadopoulos, PhD, of the Sidney Kimmel Comprehensive Cancer Center, discusses early detection as the key to reducing cancer mortality and the lack of tests for many malignancies. Liquid biopsies have the potential to screen for various tumor types, albeit with varying levels of...
Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors
Maria Alma Rodriguez, MD, of The University of Texas MD Anderson Cancer Center, discusses the need for various types of vaccinations in patients with cancer, who are vulnerable to infection while under active treatment and whose immune deficits may persist long after treatment is finished. Dr....
Association of Chromosome 3p25.3 Gain With Cisplatin Resistance and Outcomes in Male Malignant Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Timmerman et al found that chromosome 3p25.3 gain was present in all cisplatin-resistant germ cell tumor (GCT) lines in vitro; was more common in patients with relapsed or cisplatin-resistant male type II GCTs; and was associated with poorer...
Ara Klijian, MD, on Lung Cancer: Operability in Patients With Poor Pulmonary Function
Ara Klijian, MD, of Scripps Health, discusses findings on the safety of AVATS (awake video-assisted thoracic surgery), a procedure that may benefit select patients, including those whose early non–small cell lung cancer was previously deemed inoperable due to poor pulmonary function. Performed...
New Research Encourages Harnessing Health Technology to Help Patients With Cancer Quit Smoking
New research published by Ramsey et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that the inclusion of the smoking cessation tool Electronic Health Record–Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) into electronic health records may increase...
Report Finds Targeting IL-6 May Help to Relieve Immunotherapy Side Effects
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events caused by immunotherapy by targeting the cytokine interleukin-6 (IL-6). The study, published by Hailemichael et al in Cancer Cell, establishes a proof of concept ...
Christine A. Iacobuzio-Donahue, MD, PhD, on Pancreatic Cancer: Novel Insights Into Genetics and Evolution
Christine A. Iacobuzio-Donahue, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses her research on the evolutionary features of advanced stage pancreatic cancers and the insights that may be used to help improve patient outcomes (Abstract PL05).
ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to...
MSK Introduces The Starr Foundation Program for Discovery Science
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering initiative made possible by a $50 million gift from The Starr Foundation. The program will support the work of scientists at the Sloan Kettering...
NCCN Announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center Joins Member Institutions
The National Comprehensive Cancer Network® (NCCN®) recently announced that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the not-for-profit alliance of leading cancer centers as the 32nd member institution. NCCN was founded by 13 original Member Institutions in...
Penn Medicine Appoints Robert Vonderheide, MD, DPhil, to Second 5-Year Term as Director of Abramson Cancer Center
Robert H. Vonderheide, MD, DPhil, has been appointed to a second 5-year term as Director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 U.S. Food and Drug Administration approvals in oncology for therapies based on studies...
David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center
Yale Cancer Center and Smilow Cancer Hospital welcome David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology) and a member of the Center for Molecular and Cellular Oncology (CMCO). Dr. Braun cares for patients with kidney cancer. Dr. Braun received his PhD in Computational Biology ...
Sam Mbulaiteye, MBChB, MPhil, MMed, Named 2022 Scientist of the Year by Lymphoma Foundation of America
Sam Mbulaiteye, MBChB, MPhil, MMed, senior investigator in the Infections and Immunoepidemiology Branch, in the Division of Cancer Epidemiology & Genetics of the National Cancer Institute, was recently recognized by the Lymphoma Foundation of America with its 2022 Scientist of the Year Award....
J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude
J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...
AACR Honors Lee Ellis, MD, for Contributions to Education and Training in Cancer Research
The American Association for Cancer Research (AACR) has named Lee Ellis, MD, Professor of Colon and Rectal Surgery at The University of Texas MD Anderson Cancer Center, Houston, as the 2022 recipient of the AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in...
FDA Approvals in Hematologic Oncology 2021–2022
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in hematologic oncology. Axicabtagene Ciloleucel: On April 1, 2022, axicabtagene ciloleucel (Yescarta) was approved for adult patients with...
Expert Point of View: Laurie H. Sehn, MD, MPH
The moderator of the session, Laurie H. Sehn, MD, MPH, Clinical Professor at the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, called the results of the TRANSFORM trial “quite remarkable” and said chimeric antigen receptor (CAR) T-cell therapy has the...
TRANSFORM: Lisocabtagene Maraleucel Improves Outcomes in Relapsed or Refractory Large B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel could prove to be the new standard-of-care treatment for patients with relapsed or refractory large B-cell lymphoma in the second-line setting, according to data presented at the 2021 American Society of Hematology (ASH)...
Can AI Assist in Predicting Spinal Fractures in Patients With Cancer?
A new study published by Ahmadian et al in the International Journal for Numerical Methods in Biomedical Engineering suggests how scientists may use artificial intelligence (AI) to predict how cancer may affect the probability of fractures along the spinal column. The report described how the...
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer
On May 4, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. According to the approval, patients had to have received a prior anti-HER2–based regimen either in the...
Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, discusses the battle against treatment resistance and how to overcome it, as well as the power of observational clinical data in precision oncology, derived largely from his experience with Project GENIE, and the role of genetic...
Study Examines Link Between Emphysema and Lung Cancer Risk
Computed tomography (CT)-detected emphysema may be linked to a higher risk of lung cancer, a risk that increases with emphysema severity, according to a new study published by Yang et al in the journal Radiology. Lung cancer is the primary cause of cancer-related death worldwide. However, lung...
Study Reports New Potential Target for CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has made an impact on the treatment of certain blood cancers, but in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor targets not expressed in vital tissues. In a new study ...
Do AYA Cancer Survivors Face a Higher Risk of Developing and Dying From a New Primary Cancer?
New findings published by Hyuna Sung, PhD, and colleagues in the Journal of the National Cancer Institute showed that 5-year survivors of adolescent and young adult (AYA) cancer in the United States have a higher risk of developing—and nearly double the risk of dying from—a new primary cancer,...
Research Suggests Over Half of Eligible Women Would Prefer Self-Sampling for Cervical Screening
According to the results of a new study published by Drysdale et al in the Journal of Medical Screening, 51.4% of women preferred self-sampling for human papillomavirus (HPV)-based cervical cancer screening, compared to 36.5% who preferred being tested by a clinician. The findings came from a...
ASCO’s CancerLinQ® and Atropos Health Collaborate to Harness Real-World Data to Provide Point-of-Care Informatics Consult to Oncologists
ASCO’s CancerLinQ® and Atropos Health announced today a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.Atropos Health and CancerLinQ will work together to provide a...
Case Study Examines Differences Between AI and Radiologist Perception in Breast Cancer Screening
Radiologists and artificial intelligence (AI) systems yield significant differences in breast cancer screenings, a team of researchers has found. The case study by Makino et al, which appears in the journal Nature Scientific Reports, reveals the potential value of using both human and AI methods in ...
Study Finds Long-Term Increase in Cancer Risk After High Childhood BMI
Men who had a high body mass index (BMI) as children are at an elevated risk of obesity-related cancer later in life, even if their weight was normal in young adulthood, according to a new study from researchers at the University of Gothenburg, Sweden. Célind et al published their findings in the...
Cancer Screening Accessibility Among Native Americans
In a scientific e-poster presented during the 2022 American Roentgen Ray Society Annual Meeting in New Orleans, Peña et al noted that American Indian and Alaskan Native populations have nearly three times higher incidence rates of lung and colorectal cancer than other ethnic groups. These patterns...
Cancer Rates Declining in Canada, but Cases and Deaths Increasing Because of Demographic Factors
Overall cancer rates in Canada are declining, but the number of cases and deaths are increasing slightly because of population growth and an aging population, according to a new study published by Brenner et al in CMAJ (Canadian Medical Association Journal). The study is the result of a...
Patients With Cancer Face Greater Risks From Abdominal Aneurysm Repair
Elective abdominal aortic aneurysm repair in patients with a cancer diagnosis is associated with several poor postoperative outcomes, according to a newly published study from researchers at the University of Missouri School of Medicine. Roush et al reported their findings in the Journal of...
Study Identifies Genetic Changes in Patients With Barrett’s Esophagus That Progresses to Esophageal Cancer
Using whole-genome sequencing to contrast genomic alterations in patients with stable Barrett’s esophagus compared to patients whose Barrett’s progressed to esophageal adenocarcinoma, Paulson et al reported that DNA changes presaging esophageal cancer can be spotted years before cancer develops....
Increased Risk of Cancer in Early Life Among Individuals With Autism Spectrum Disorders
In the largest and most detailed population-based cohort study to date, researchers from the Karolinska Institute in Stockholm found that individuals with autism spectrum disorders, when present with comorbid intellectual disability and/or birth defects, were at a higher risk of cancer in early...
Gut Microbiome May Alter Response to Cancer Therapy
Recent findings with the use of sequencing technology have suggested that the gut microbiome may play a role in the treatment of cancer. A review paper published in JAMA Oncology by Liu and Shah captured the current understanding of the connection between the gut microbiome and therapeutic response ...
Study Finds CAR T-Cell Therapy Outcomes, Side Effects Are Similar in Black and Hispanic Patients Compared to White and Asian Patients
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and multiple myeloma. However, Black and Hispanic patients were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration...
Updated Guidance for COVID-19 Vaccination From NCCN Recommends Fifth mRNA Shot (Second Booster Dose) for Immunocompromised People
The National Comprehensive Cancer Network® (NCCN®) has released the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. The updated recommendations point to two booster vaccine doses for people who are immunocompromised (meaning three...
Matthew R. Smith, PhD, MD, on Prostate Cancer: Phase III Data on Darolutamide, Androgen Deprivation, and Docetaxel
Matthew R. Smith, PhD, MD, of Massachusetts General Hospital Cancer Center, discusses overall survival findings from the ARASENS trial, which assessed the efficacy of the androgen receptor inhibitor darolutamide vs placebo in combination with androgen-deprivation therapy and docetaxel for patients...
Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications
Priscilla K. Brastianos, MD, of Harvard Medical School and Massachusetts General Hospital, talks about her efforts to better understand how brain metastases evolve genomically and to test such agents as abemaciclib, paxalisib, and entrectinib, which may stop their growth. Palbociclib, a CDK...
Timothy A. Yap, MBBS, PhD, on Ovarian, Breast, Pancreatic, and Prostate Cancers With Genetic Mutations: A First-in-Human Trial of AZD5305
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the PETRA study, a first-in-class, first-in-human trial of the next-generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2, or RAD51C/D mutations in advanced or metastatic...
Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses how research is building on the success of first-generation PARP inhibitors in the clinic and the potential of novel potent PARP1-selective inhibitors, which may lead to improved patient outcomes. Given...
Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response defects....
Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin
Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. The combination appeared to result in many complete pathologic responses (Abstract CT009).
Lillian L. Siu, MD, on Looking Toward the Future of Clinical Research and Clinical Trials
Lillian L. Siu, MD, of Canada’s Princess Margaret Cancer Centre, discusses biomarker-driven precision cancer medicine, the optimal sequencing of immunotherapy (IO) with standard treatments in curative settings, IO targets beyond PD-1/PD-L1 and combinatorial strategies, and next-generation adoptive...
Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment
Marcia R. Cruz-Correa, MD, PhD, of the University of Puerto Rico Comprehensive Cancer Center, discusses a way to possibly transform cancer outcomes by teaming up basic scientists, clinical researchers, and community advocates to work together, decode the complexity of cancer, and find points at...
Two Studies Examine Use of Proton-Beam Therapy in the United States
Two new, large studies led by researchers at the American Cancer Society showed an increase in the use of proton-beam therapy for patients with cancer in the United States during the past decade. However, Black patients were less likely to receive proton-beam therapy than White patients, and the...
